Skip to content
Novartis
-
Novartis breaks ground on Texas’ first radioligand therapy site to secure U.S. cancer supply chain
The Denton facility will become Novartis’ first manufacturing site in Texas and its fifth radioligand therapy production site in the country.
-
Novartis gains FDA approval for Itvisma gene therapy to treat spinal muscular atrophy
Itvisma works by delivering a functional copy of the survival motor neuron 1 (SMN1) gene through a single, fixed-dose intrathecal injection.